TTRX: Turn Therapeutics Inc. insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Institutional ownership (Q2 2026)
29 institutions reported holding $8.48M of Turn Therapeutics Inc. on Form 13F (20 the quarter before). 10 opened a new position and 2 sold out. Shares held by institutions: +150%.
| Largest holders | Shares | Value |
|---|---|---|
| SteelPeak Wealth, LLC | 249,456 | $1.82M |
| IEQ CAPITAL, LLC | 227,396 | $1.66M |
| DDFG, Inc | 107,829 | $787K |
| VANGUARD CAPITAL MANAGEMENT LLC | 74,301 | $542K |
| Wellington Shields & Co., LLC | 65,732 | $480K |
| MILLENNIUM MANAGEMENT LLC | 60,551 | $442K |
| BlackRock, Inc. | 38,591 | $282K |
| Bridgewater Advisors Inc. | 27,326 | $242K |
| Aaron Wealth Advisors LLC | 32,564 | $238K |
| Tamar Securities, LLC | 30,000 | $219K |
Clinical trial readouts
1 Phase 2 or 3 trials by Turn Therapeutics Inc. with a primary completion date in the last 90 days or the next 12 months and no results posted yet, from ClinicalTrials.gov. (est.) = company estimate.
| Primary completion | Drug | Condition | Phase | Patients | Status | Trial |
|---|---|---|---|---|---|---|
| 2027-01-20 (est.) | GX-03 | Eczema Atopic Dermatitis | Phase 2/3 | 190 | Recruiting | NCT07355075 |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.